{"id":"hum0292","version":1,"url":"https://humandbs.dbcls.jp/research/hum0292/v1","datePublished":"2021-09-24","versions":[{"version":1,"datePublished":"2021-09-24"}],"title":{"ja":"去勢抵抗性前立腺癌の最適医療の実現に向けた血液ゲノムマーカーの開発","en":"Development of blood-based biomarkers for precision medicine in castration-resistant prostate cancer"},"summary":{"aims":{"ja":"血中遊離DNA（cell free DNA：cfDNA）および血中循環腫瘍細胞（circulating tumor cells：CTC）のゲノム解析に基づく、去勢抵抗性前立腺がん（castration-resistant prostate cancer：CRPC）に対する各種薬剤（アビラテロン、エンザルタミド、ドセタキセル、カバジタキセル）効果予測システムの開発","en":"To develop predictive biomarkers for the treatment of castration-resistant prostate cancer (CRPC) such as abiraterone, enzalutamide, docetaxel, and cabazitaxel based on genomic analyses of cell-free DNA (cfDNA) and circulating tumor cells (CTC)."},"methods":{"ja":"アビラテロンまたはエンザルタミド投与前のCRPC患者100名を国内17施設で集積。薬剤投与前採血より、cfDNAと白血球からDNAを抽出。DNA断片に分子バーコードを付加した上でシークエンスライブラリを作成し、Illumina NovaSeqを用いてターゲットシークエンス（88遺伝子のエクソン領域を対象）を行った。","en":"One hundred CRPC patients eligible for treatment with either abiraterone or enzalutamide were prospectively enrolled at 17 institutions in Japan. cfDNA and paired lymphocyte DNA per patient were used for sequencing library preparation, and unique molecular identifiers were added. Targeted sequencing was performed using Illumina NovaSeq (Our custom gene panel captures the exonic regions of 88 genes)."},"targets":{"ja":"アビラテロンまたはエンザルタミド投与前の去勢抵抗性前立腺がん患者100名","en":"100 CRPC patients eligible for abiraterone or enzalutamide"},"url":{"ja":null,"en":null}},"listingSummary":{"methods":{"ja":"配列決定","en":"Sequencing"},"targets":{"ja":"去勢抵抗性前立腺癌：100症例\n（日本人）","en":"100 CRPC patients\n(Japanese)"},"typeOfData":{"ja":"NGS\n（Target Capture）","en":"NGS\n(Target Capture)"}},"releaseNote":{"ja":"アビラテロンまたはエンザルタミド投与前の去勢抵抗性前立腺がん100症例の末梢血から抽出したcfDNAおよび白血球DNAを用いた88遺伝子のTarget Capture Sequencing解析データをfastqファイルにて提供する。","en":"cfDNA and paired lymphocyte DNA extracted from peripheral blood of 100 patients with castration-resistant prostate cancer were used for the target capture sequencing analysis. Fastq files are provided."},"dataProviders":[{"name":{"ja":"赤松 秀輔","en":"Shusuke Akamatsu"},"organization":{"name":{"ja":"京都大学大学院医学研究科 泌尿器科学","en":"Department of Urology, Graduate School of Medicine, Kyoto University"}}}],"researchProjects":[],"grants":[{"title":{"ja":"血中遊離DNA解析を応用した前立腺癌のDNA修復遺伝子異常の生物学的特性の解明","en":"Understanding the biological mechanisms of defective DNA damage repair in prostate cancer using cell-free DNA analysis"},"agency":{"ja":"科学研究費助成事業 基盤研究（B）","en":"KAKENHI Grant-in-Aid for Scientific Research (B)"},"grantIds":["20H03814"]},{"title":{"ja":"日本人前立腺癌患者におけるDNA修復遺伝子の生殖細胞系列・体細胞変異の頻度","en":"The prevalence of germline and somatic DNA repair gene mutations in Japanese prostate cancer patients"},"agency":{"ja":"アストラゼネカ Externally Sponsored Researchプログラム","en":"AstraZeneca Externally Sponsored Scientific Research"},"grantIds":["NCR-17-13159"]},{"title":{"ja":"去勢抵抗性前立腺癌生検組織を用いたエンザルタミド治療効果予測因子の検討","en":"Identification of factors predicting response to enzalutamide using tissues of castration-resistant prostate cancer"},"agency":{"ja":"アステラス 研究助成金","en":"Astellas Research Grant"},"grantIds":null}],"relatedPublications":[{"title":"Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer","doi":"https://doi.org/10.1158/1078-0432.CCR-21-2328","datasets":["JGAD000441"]}],"datasets":["JGAD000441"],"controlledAccessUsers":[]}